ANCA
|
Anti-neutrophil cytoplasmic antibody |
APOL1
|
Apolipoprotein L1 |
CAAR
|
Chimeric autoantibody receptor |
c-mip
|
c-maf inducing protein |
CMV
|
Cytomegalovirus |
CNI
|
Calcineurin inhibitor |
CTLA4
|
Cytotoxic T-lymphocyte antigen 4 |
DSA
|
Donor specific antibody |
EBV
|
Ebstein-Barr virus |
ESKD
|
End stage kidney disease |
FSGS
|
Focal segmental glomerulosclerosis |
GBM
|
Glomerular basement membrane |
HHV-8
|
Human herpesvirus-8 |
HLA
|
Human leukocyte antigen |
ICI
|
Immune checkpoint inhibitor |
IgA
|
Immunoglobulin A |
IL
|
Interleukin |
KSHV
|
Kaposi’s sarcoma herpesvirus |
MCD
|
Minimal change disease |
MHC
|
Major histocompatibility complex |
MN
|
Membranous nephropathy |
MPGN
|
Membranoproliferative glomerulonephritis |
mTOR
|
Mammalian target of rapamycin |
NELL-1
|
Neural epidermal growth factor-like 1 |
NK
|
Natural killer |
PCDH7
|
Protocadherin 7 |
PD-1
|
Programmed cell death 1 |
PLA2R
|
Phospholipase A2 receptor |
sHLA-G
|
Soluble HLA-G |
TGF-β
|
Transforming growth factor β |
THSD7A
|
Thrombospondin type-1 domain-containing 7A |
TMA
|
Thrombotic microangiopathy |
TPE
|
Therapeutic plasma exchange |
VEGF
|
Vascular endothelial growth factor |